AC Immune
ACIU | NASDAQ
$2.09
-$0.04 (-1.88%)
At close: Nov 16, 2026, 4:00 PM ET
$2.09
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 7:30 PM ET
AC Immune Company Profile
Company profile explainedCompany Profile
AC Immune S.A. is a biotech firm operating at the clinical stage, dedicated to pioneering, formulating, and advancing therapeutic agents and diagnostic tools. Its core mission is addressing neurodegenerative conditions rooted in protein misfolding, both preventatively and therapeutically. Leveraging its proprietary SupraAntigen and Morphomer platforms, the company engineers a range of vaccines, antibodies, and small molecules specifically designed to engage with aberrantly folded proteins implicated across various neurodegenerative disorders. Its pipeline features Crenezumab, a humanized, conformation-specific monoclonal antibody currently undergoing a Phase II clinical prevention trial for Alzheimer's disease (AD). Additionally, AC Immune is advancing ACI-24, an anti-Abeta vaccine candidate, which is in Phase II clinical evaluation for AD and has successfully completed a Phase Ib study for Down syndrome. Other key candidates include ACI-35, an anti-Tau vaccine candidate that has finished Phase Ib clinical assessment, and a Tau-positron emission tomography (PET) imaging tracer, also in Phase II development. Furthermore, the company is engaged in the research and development of small molecule inhibitors to prevent Tau aggregation, targeting AD and various NeuroOrphan indications. Early-stage efforts include discovery and preclinical programs for a spectrum of neurodegenerative diseases, encompassing diagnostic agents aimed at TDP-43, alpha-synuclein, and NLRP3. The company maintains strategic partnerships and licensing agreements with key industry players such as Genentech, Inc., Biogen International GmbH, Janssen Pharmaceuticals, Inc., Life Molecular Imaging SA, Eli Lilly and Company, and WuXi Biologics. Founded in 2003, AC Immune S.A. is headquartered in Lausanne, Switzerland.
Key Executives
| Name | Position |
|---|---|
| Martin Zugel | Interim CEO & Chairman of the Board |
| Christopher Roberts | Chief Financial Officer & Vice President of Finance |
| Piergiorgio Donati | Chief Operating Officer |
| Bojana Portmann | SVP of Intellectual Property,Intellectual Property & Business Development |
| Francesca Capotosti | Senior Vice President of Research |
| Gary Anthony Waanders | Senior Vice President of Investor Relations & Corporate Communications |
| Günther Staffler | Executive Vice President of Development |
| Julien Rongere | Senior Vice President of Regulatory Affairs & Quality Assurance |
| Mark Danton | Executive Vice President of Information Systems & Artificial Intelligence |
| Matthias Maurer | Senior Vice President & General Counsel |
| Oliver Sol | Vice President & Head of Clinical Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 09, 2026 | 3/A | [Amend] Filing |
| Oct 09, 2026 | 3 | Filing |
| Oct 02, 2026 | 6-K | Filing |
| Sep 23, 2026 | 6-K | Filing |
| Sep 03, 2026 | 6-K | Filing |
| Aug 20, 2026 | 6-K | Filing |
| Aug 11, 2026 | 6-K | Filing |
| Aug 05, 2026 | 6-K | Filing |
| Jun 30, 2026 | 6-K | Filing |
| Jun 15, 2026 | 4 | Filing |
AC Immune
| Country | Switzerland |
| IPO Date | Sep 23, 2016 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 106 |
| CEO | Martin Zügel |
Stock Details
| Ticker Symbol | ACIU |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001651625 |
| CUSIP Number | H00263105 |
| ISIN Number | CH0329023102 |
| SIC Code | 2834 |
Add to Watchlist
Select watchlists to add or remove ACIU